NCT00913653View on ClinicalTrials.gov

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2009

Conditions
Heart Failure
Interventions
DRUG

LCZ696

Trial Locations (1)

117198

GOUVPO Russian Peoples´ Friendship University, Center of Applied, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY